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INTRODUCTIONANDAIMS:Obesity is an independent risk factor for chronic kid-
ney disease (CKD) and for CKD progression to end-stage renal disease. Creatinine-
based formulas are widely used in pediatrics and clinical research to estimate glomeru-
lar filtration rate (eGFR). In overweight and obese adolescents, conventional indexa-
tion of eGFR to body surface area (BSA)may bemisleading.We aimed to evaluate the
performance of the bedside eGFR Schwartz formula, absolute eGFR and eGFR adjusted
to ideal body weight (BSA-IBW-adjusted eGFR) in a nationwide cohort of US
adolescents.
METHODS:We analyzed the association between bodymass index (BMI) and the bed-
side eGFR Schwartz formula, absolute eGFR and BSA-IBW-adjusted eGFR among ado-
lescents of a US representative cohort, the continuous National Health and Nutrition
Examination Survey (NHANES) 1999-2016. The analysis was restricted to nonpreg-
nant adolescents aged 12 to 17 years. We excluded participants with low weight-for-age
(BMI z-score< 2), those taking antihypertensive drugs and individuals with missing
data regarding plasmatic creatinine, albuminuria or BMI.We used the bedside-
Schwartz formula to calculate eGFR (mL/min/1.73m2) and to derive both absolute
eGFR (mL/min) and BSA-IBW-adjusted eGFR (mL/min/1.73m2). Categories of BMI
were defined according to theWorld Health Organization reference data as normal
weight (-2 BMI z-scoreþ1), overweight (þ1< BMI z-scoreþ2) and obese
(BMI z-score>þ 2). The association between BMI categories and eGFR was evaluated
with logistic regression unadjusted and adjusted for age, sex, race, parental educational
level, family’s income, hypertension, diabetes and dyslipidemia. We also evaluated the
association between BMI categories and hyperfiltration (defined as eGFR 120 mL/
min/m2 or 120mL/min) in unadjusted and adjusted models.
RESULTS:We included 10175 adolescents (51.3%male) with a mean age of 14.5 (6
1.7) years. According to BMI category, 5462 (53.7%) were normal-weight, 2396
(23.6%) were overweight, and 2317 (22.8%) were obese. The mean bedside-Schwartz
eGFR in overweight (99.86 19.3 mL/min/1.73m2) and obese adolescents (102.26
20.3 mL/min/1.73m2) was not significantly different from that in normal-weight ado-
lescents (100.06 18.8 mL/min/1.73m2). Absolute eGFR were higher in overweight
(100.56 19.1 mL/min) and obese (119.86 26.4mL/min), compared to normal-weight
(89.56 16.1mL/min) adolescents. BSA-IBW-adjusted eGFR were higher in overweight
(112.56 22.1 mL/min/1.73m2) and obese (132.86 28.9 mL/min/1.73m2), compared
to normal-weight (100.26 18.9 mL/min/1.73m2) adolescents. Logistic regression
models to predict hyperfiltration showed different odds according to BMI category
when eGFR was estimated using absolute eGFR and BSA-IBW-adjusted eGFR, but not
when the bedside Schwartz formula was used.
CONCLUSIONS:Differences in eGFR across normal-weight, overweight, and obese
adolescents were detected using absolute and BSA-IBW-adjusted eGFR. These differen-
ces were inapparent when using the bedside Schwartz formula. Further research is
needed to identify themost accurate approach to estimate GFR in overweight and obese
adolescents.
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INTRODUCTIONANDAIMS: Triferic (FPC) is approved as an iron replacement
product to maintain hemoglobin in adult patients receiving chronic hemodialysis.
Triferic rapidly transfers across the dialyzer membrane, donates iron directly to trans-
ferrin, and is cleared from the circulation with a half-life of 2 to 4 hr. The current study
examined the pharmacokinetics (PK) of Triferic administered via dialysate and intrave-
nously (IV) to pediatric hemodialysis patients.
METHODS: This was an open-label, two period single dose study conducted in 22
CKD-5HD patients between ages 1 and 17 years. Each patient received 2 treatments in
sequential order. Blood was drawn for serum iron profile at defined times for PK analy-
sis. The treatments were Triferic 0.07mg Fe/kg IV into the post-dialyzer blood line
(FPC-IV) and Triferic 2 lM (110 lg Fe/L) via HD (FPC-HD). HDwas conducted for
3-4 hours and IV infusions were administered into the pre-dialyzer blood tubing using
the on-machine pump during HD. An estimate of iron delivered at the dialysis session
was calculated by using partial AUC based on the IV dose.
RESULTS: A total of 22 subjects, age range 1-17 years were enrolled. A total of 21 sub-
jects provided PK data. There was greater inter-individual variability and lower peak
iron levels in the younger age group patients. Triferic-HD showed a similar intradialytic
and post-dialysis iron profile as Triferic-IV in all age groups. The results of mean intra-
dialytic change in serum Fe with HD and IV, and average dose administered via HD (Fe
HD) are presented in Table 1.
Table 1: Triferic Pediatric Results
max Fe HD
DoseAUC
mg
Fe HD
DoseAUC
mg/kg
TSAT
HDMax
(SD)
1-5 year 3 92.7 (35.9) 14.4 34.7 1.47 0.08 34.3
6 to
11 year
2 127 (27.4) 21.4 43.8 1.67 0.06 52.5 (41.2)
12-17
year
16 131 (51.5) 41.1 72.7 4.97 0.09 87.3 (28.2)
Non-compartmental analysis showed that Triferic iron was rapidly cleared with a t1=2 of
approximately 2 hr. Triferic was well tolerated with no drug related adverse effects.
CONCLUSIONS: This study shows that Triferic iron can be delivered to pediatric
CKD-5HD patients either intravenously when using solid bicarbonate cartridge/bag
system or via the dialysate. Triferic was well tolerated. The results suggest that IV
administration in patients below age 12 be started at 0.1 mg Fe/kg and increased as
needed to achieve a post HD target TSAT of around 75%. Patients above 50 kg in
weight should receive the full adult dose of 6.75 mg IV.
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INTRODUCTIONANDAIMS:Chronic kidney disease (CKD) is characterized by a
gradual reduction in kidney function. The prevalence of CKD in the pediatric popula-
tion is low but with such early CKD onset often results in devastating long-term conse-
quences. A urinary proteome-based classifier, termed CKD273, has been validated in
different studies, in the context of diagnosis and prognosis of CKD in adults. However,
CKD273 was never evaluated in pediatric patients. Therefore, the aim of this study is to
exploit and assess the diagnostic performance of CKD273 classifier in the pediatric pop-
ulation. Furthermore, we investigate whether an adjustment of CKD273 classifier
according to a childhood population is necessary.
METHODS: In this retrospective study, we analyzed the lowmolecular weight urinary
proteome (0.8-20 kDa) of 358 subjects aged 0 to 20 years. The cohort consisted of 86
patients with different CKD etiologies (e.g. focal segmental glomerulosclerosis, mini-
mal change disease, IgA nephropathy, etc.) and all CKD stages and 272 controls. The
receiver operating characteristic (ROC) curve analysis with calculation of areas under
the curve (AUC), sensitivity and specificity, was performed usingMedCalc software.
RESULTS: First, we evaluated the performance of CKD273 using the previously estab-
lished CKD cut-off value of 0.343 for adults in this pediatric cohort, yielding an AUC of
0.931 and a specificity of 97.8%whereas sensitivity was only 65.1%. Therefore, we fitted
amodified cut-off for children with CKD to 0.053. Applying this adapted cut-off,
CKD273 predicted CKDwith a sensitivity of 86.1% and a specificity of 88.6%.
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Furthermore, evaluation of CKD273 with the pediatric cut-off across different age
groups demonstrated high AUC, sensitivity and specificity for the prediction of CKD in
children (Table).
CONCLUSIONS: This study demonstrates that CKD273, with the use of an adapted
cut-off, can become an important tool for the diagnosis of CKD in childhood. Future
work includes the analysis of an additional cohort of children with CKDwith follow-up
information about the progression to CKD to verify whether the classifier with the
pediatric cut-off also identifies progressive CKD as it does in adults.
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INTRODUCTIONANDAIMS: In 1998, an ESPN survey showed substantial dispar-
ities in paediatric renal care between European countries. Through the following 20
years ESPN aimed at harmonizing renal care in all countries in Europe. In 2017, we sent
a follow-up questionnaire on paediatric renal care evaluating the current status of renal
health policies for children.
METHODS: Aweb-based survey was sent to the presidents or representatives of
national societies of paediatric nephrology in 44 European countries.
RESULTS:Data was reported from 42 out of 44 countries, including Israel, Kazakhstan
and Turkey. The number of paediatric nephrologists per million child population
(pmcp) aged<15 years increased from 1998 to 2017 in 70% of European countries.
The numbers remained stable in 9 (21%) of countries. A paediatric renal care service
was newly established in 4 (9%) of countries. Comparing 2017 with 1998, paediatric
dialysis facilities for end stage kidney disease (ESKD) were available in 95% vs. 90% of
European countries. Themedian number of dialysis centers for ESKD in 2017 com-
pared with 1998 was similar: 1.8 pmcp (IQR: 0.4-6.3) vs. 1.5 pmcp (IQR: 0-5.0).
Paediatric renal transplantation (RTx) becamemore widely available in 2017 if com-
pared with 1998: 93% vs. 55% of countries (p<0.0001). Themedian number of RTx
centers was higher in 2017 compared with 1998: 1.2 (range 0.2-2.3) vs. 0.4 (0-3.5)
pmcp. Eighty-six percent of countries reported data to the paediatric ESPN-ERA/
EDTA Registry for renal replacement therapy. Light, immune fluorescence and electron
microscopy of kidney tissue were performed in 91% of European countries. Genetic
diagnostics for inherited kidney diseases were available in 78% of countries. Transition
programs from paediatric to adult renal care existed in 52% of countries. Psychosocial
support was available in specialized paediatric nephrology centers in 83% of countries.
Renal dietitians were present in 62% of countries. Paediatric nephrology was recog-
nized as a subspecialty in 75% of European countries. National societies of paediatric
nephrology existed in two thirds of countries. Institutional support for paediatric
nephrologists to attend international meetings was provided in half of the European
countries.
CONCLUSIONS:Our comparative analysis of paediatric renal care services in 42
European countries in 2017 and 1998 years revealed that paediatric nephrology has
become a well-established subspecialty in paediatrics and in nephrology. ESPNwill
continue to further improve paediatric kidney care in Europe by harmonizing remain-
ing diversity of renal care for children and adolescents.
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INTRODUCTIONANDAIMS: The action of glucocorticoids is to switch off activated
inflammatory genes. The activated glucocorticoid receptors (GR) interact with co-
repressor molecules to impair NFjB-associated coactivator activity, reducing histone
acetylation, chromatin remodelling. Reduction in histone acetylation occurs via
recruitment of histone deacetylase (HDAC) 2 to the activated inflammatory gene com-
plex by activated GR, resulting in efficacious suppression of activated inflammatory
genes within the nucleus.To evaluate the effect HDAC 2 on P-gp expression.
METHODS: Total 25 subjects are considered in the study out of which 10 are patients
with Steroid Sensitive Nephrotic Syndrome (SSNS), 10 are patients with Steroid
Resistant Nephrotic Syndrome (SRNS) and 5 are healthy control (HC). The mRNA
expression was analyzed on blood samples in SR patients (mean age 8.4363.8), SS
patients (mean age7.5463.5) with healthy control (HC) (mean age 4.1363.37).
Peripheral bloodmononuclear cells (PBMCs) were isolated from heparinized blood
using ficoll method. PBMCs were treated with 1mMof Theophylline (stimulator of
HDAC2) and 0.8mMof Trichostatin A (inhibitor of HDAC2) for a period of 48 hours.
Total RNAwas isolated using trizol method from PBMCs. Real time quantitative PCR
was performed using light cycler LC480 using SYBR green PCR technology with SYBR
premix relative gene expression levels were calculated and normalized to the corre-
sponding levels of the housekeeping gene (GAPDH).
RESULTS: Biochemical parameters were found to be significant different in Serum
Albumin (SSNS¼2.976.88, SRNS¼ 2.176.89, p¼0.017) and proteinuria
(SSNS¼18.1862.09, SRNS¼2836173.45, p¼0.001). Percentage viability for
Theophylline at 1mMand of Trichostatin A at 0.8mMwas found to be 81%. mRNA
expression of HDAC2 in SSNS patients no significant difference is found with healthy
control (p¼0.9894), while in SRNS patients expression of mRNA is downregulated
which is significant (p¼0.0018). Expression of P-gp in SSNS patients is downregulated
to compared with healthy control (p¼0.004), while in patients with SRNSmRNA
expression is upregulated which is significant (p¼0.035) with HC. Treatment with
Theophylline-1mM reducedmRNA expression of P-gp in SSNS and HC but not upto
the levels of SRNS (Figure 1). Trichostatin A-0.8 mM treatment in SSNS patient’s upre-
gulated expression level of P-gp but not in consistence with SRNS patients (Figure 2).
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